Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about Ascelia Pharma:
TOP STORIES
Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million
2025-09-23
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, [ …
TOP STORIES
Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration
2025-09-03 10:10:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the New Drug Application (NDA) for Orviglance® [& …
TOP STORIES
Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1
2025-04-16 17:55:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, [ …
Upcoming Events
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Quarterly Report Q3 2025: Orviglance NDA Submitted to the FDAHalf-Year Report 2025: Orviglance NDA Submission ApproachingQuarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA SubmissionAnnual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study CompletionQ4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study